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Abstract
Background: GenIO is a novel web-server, designed to assist clinical genomics researchers and medical doctors in
the diagnostic process of rare genetic diseases. The tool identifies the most probable variants causing a rare disease,
using the genomic and clinical information provided by a medical practitioner. Variants identified in a whole-genome,
whole-exome or target sequencing studies are annotated, classified and filtered by clinical significance. Candidate genes
associated with the patient’s symptoms, suspected disease and complementary findings are identified to obtain a small
manageable number of the most probable recessive and dominant candidate gene variants associated with the rare
disease case. Additionally, following the American College of Medical Genetics and Genomics and the Association of
Molecular Pathology (ACMG-AMP) guidelines and recommendations, all potentially pathogenic variants that might be
contributing to disease and secondary findings are identified.
Results: A retrospective study was performed on 40 patients with a diagnostic rate of 40%. All the known genes that
were previously considered as disease causing were correctly identified in the final inherit model output lists. In
previously undiagnosed cases, we had no additional yield.
Conclusion: This unique, intuitive and user-friendly tool to assists medical doctors in the clinical genomics
diagnostic process is openly available at https://bioinformatics.ibioba-mpsp-conicet.gov.ar/GenIO/.
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Background
The advances in genetics, and the growing availability of
health and genetic data, are making personal genomics a
clinical reality. Clinical implementation of whole-
genome sequencing or whole-exome sequencing as a
single and primary test, will provide a higher diagnostic
yield than conventional testing, while decreasing the
number of genetic tests and ultimately the time required
to reach a genetic diagnosis [1]. Genetic risk communi-
cation and genetic diagnosis will rapidly broadened in
scope and practice, as emerging genomic technologies
allow more medical doctors to access information re-
garding their patients’ genetic makeup [2].
Here we present GenIO, a clinical genomics webtool
to assist in the clinical genomics diagnostic process.
Through our web server the user uploads the patient’s
genetic information as a variant call format (VCF) file,
and enter the patient’s clinical information as structured,
comprehensive and well-defined terms for observed
symptoms, suspected disease and complementary fin-
dings. Starting from thousands of variants, GenIO ap-
plies different annotations and filters, in order to
identify a small number of the most probable recessive
and dominant variants associated with rare Mendelian
diseases (Fig. 1).
GenIO clinically classifies all variants using up-to-date
clinical information, and identifies those variants with
potentially functional pathogenic effects guided by the
ClinVar database annotations [3], the Mendelian Clinic-
ally Applicable Pathogenicity (M-CAP) classifier [4], and
the InterVar clinical interpretation [5] which follows the
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American College of Medical Genetics and Genomics
and the Association for Molecular Pathology (ACMG-
AMP) recommendations [6]. Additionally, GenIO re-
ports secondary findings, in alignment with the ACMG
latest recommendations for reporting of secondary find-
ings in clinical exome and genome sequencing [7].
The GenIO process assists the medical practitioner in
confirming a diagnosis for the patient case. At the mo-
ment, this crucial and time consuming annotation and fil-
tering procedure is being done either manually, by the few
geneticists able to benefit from bioinformatical support, or
by using more complex web servers such as wAnnovar
[8], Omim Explorer [9], eXtasy [10], PhenIX [11] or Phen-
Gen [12], designed for research exploration and not for
medical doctors working the diagnosis of rare diseases.
GenIO interface has been designed to minimize usage
complexity, allowing medical doctors to input a pa-
tient’s genetic makeup from a VCF file together with
the patient’s phenotype, entered as controlled vocabu-
lary terms from the Human Phenotype Ontology
(HPO) project [13] and the Online Mendelian Inherit-
ance in Man (OMIM) database (https://omim.org/) in a
precise and easy way, to obtain a clear and concise
output report (Fig. 2). This simple, intuitive and user-
friendly clinical genomics Input-Output process gives
GenIO its name.
GenIO is a unique web server, designed for medical
doctors and researchers in the field of clinical genomics
who may not have the necessary bioinformatics skills to
annotate, classify and filter variants identified in high-
throughput-sequencing studies to be able to choose the
candidate disease causative gene from a small number of




A benchmark dataset were simulated using a trustable
and freely available source of pathogenic variants in the
ClinVar public archive, their HPO associated terms, and
the exome of a healthy individual to create a set of 125
simulated cases to be tested with GenIO. The ClinVar
archive version 20,160,302 was downloaded and proc-
essed to filter out non-pathogenic variants, variants with
no solid support evidence, and variants that lacked an
OMIM registry. The resulting pathogenic gene variants
were annotated with their known HPO associated terms
downloaded from the Human Phenotype Ontology’s pro-
ject website. Then a publicly available VCF file of the exome
of a healthy individual was obtained [14]. Finally, 125
pathogenic gene variants with HPO annotations were ran-
domly chosen from the filtered and annotated ClinVar file,
and each added to different copies of a the exome of a
healthy individual, obtaining a dataset of 125 simulated
cases (pairs of VCF and HPO terms) to be tested in GenIO.
The benchmark dataset is available at https://bioinformatic
s.ibioba-mpsp-conicet.gov.ar/GenIO/tests.zip
An additional real dataset of 40 patients from the
Neurogenetics Unit in Hospital Ramos Mejía, Buenos
Aires, which were previously studied applying WES and
Sanger confirmation with a diagnostic rate of 40% (16
from 40) [15] were used to conduct a retrospective study.
The study was approved by the Ethics Committee and
Institutional Review Board of our Hospital JM Ramos
Mejia, informed written consent was obtained from the
participants, and the data were analyzed anonymously.
Finally, to further evaluate and compare the performance
of GenIO, a smaller benchmark dataset of 10 cases with
definitive diagnosis obtained from the former datasets was
Fig. 1 The GenIO pipeline. From left to right: Input parameters (VCF file and phenotype terms), GenIO pipeline, Output files (candidate recessive
and dominant variants lists, potential pathogenic variants list, annotated VCF and secondary findings)
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created to challenge other existing clinical genomics web
servers to find the causative gene under the same input
parameters.
VCF file validation
The uploaded VCF file is validated in order to check com-
pliance with the standardized VCF format version 4.0 or
higher. The VCF header should contain the format infor-
mation, and the column names and order as specified by
the Global Alliance for Genomics and Health Data Wor-
king group file format team (https://samtools.github.io/hts-
specs/). VCF columns must be tab separated, have each the
proper data type, and have no duplicated variant entries.
Only variants that have passed all the quality controls, and
hence have a PASS value in the FILTER field, will be taken
in consideration for the analysis. In this first release the
files uploaded to GenIO must be 200 MB or smaller.
Variant annotation and phenotype processing
GenIO’s variant annotation process uses Annovar [16],
Anntools [17], and SnpEff [18] to annotate all variants
with information from some of the main clinical genom-
ics databases such as ClinVar, OMIM, the Genome Ag-
gregation Database (gnomAD) [19], and dbSNP [20];
generating a merged and annotated VCF file.
GenIO’s phenotype process analyses the symptoms,
suspected disease and complementary findings entered
terms with Phenolyzer [21] to obtain the list of genes re-
lated to the patient’s disease/phenotype. Since the candi-
date genes associated to the entered phenotype are
obtained by using Phenolyzer, which has an algorithm to
predict putative disease genes, GenIO is then able to
identify disease mutations in genes not previously de-
scribed as being disease-causing.
Variant filtering and classification
GenIO’s variant filtering and classification process iden-
tifies the most probable recessive and dominant deleteri-
ous variants in the list of genes, related to the patient’s
disease/phenotype, by filtering on variant effect, popula-
tion frequency, potential impact, and quality by using
the variant_reduction script from Annovar and several
custom filters. The default inheritance model output lists
include deleterious variants with gnomAD Exome allele
frequencies < 0.1% for the recessive model, and not ob-
served in gnomAD for the dominant model. These vari-
ants are then classified by the Mendelian Clinically
Applicable Pathogenicity (M-CAP) classifier, the InterVar
ACMG-AMP clinical interpretation tool, and the ClinVar
clinical significance annotation for the medical doctor to
have a better understanding of the candidate causative
variants informed. The GenIO’s interface advanced op-
tions enables the user to enter a specific gene list of inte-
rest for analysis, and to modify the filtering thresholds of
population frequency according to the rareness of the sus-
pected condition due to default filtering frequencies might
be too low for several Mendelian disorders.
An additional list of variants with potentially functional
disease-related pathogenic effects is generated by filtering
variants in genes involved in Mendelian disorders (present
in the OMIM database); with impact on the gene product
(nonsense and frameshift mutations, splice site alterations,
Fig. 2 The GenIO user interface
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loss of stop codons, non-synonymous substitutions and
codon insertions and deletions); with gnomAD Exome al-
lele frequency < 1%; and with a clinical significance of
pathogenic or likely-pathogenic nature, obtained either
from the ClinVar database, the M-CAP classifier, or the
InterVar ACMG-AMP clinical interpretation.
GenIO creates a minimum list of secondary findings,
which includes deleterious variants found in 59 medic-
ally actionable genes (ACMG SF v2.0), recommended
for reporting in clinical genomic sequencing studies.
Server security
The GenIO application runs on a Secure HTTP Apache
web server hosted on our Bioinformatics core facility at
the Instituto de Investigación en Biomedicina de Buenos
Aires (IBioBA). All GenIO databases and third-party
programs used are locally installed on the server, so
there is no further information transferred. The user
data uploaded in the server is used for GenIO analysis
only, stored for one month, and erased afterwards.
Implementation and availability of web server
The methodology for identifying the most probable vari-
ants causing a rare disease described above is imple-
mented in the web server named GenIO, using Linux,
Apache, PHP, JavaScript architecture and is made pub-
licly available online at https://bioinformatics.ibioba-
mpsp-conicet.gov.ar/GenIO/
Results
In order to validate the tool, we conducted a retrospective
study on 40 patients with a diagnostic rate of 40% (16
from 40 cases) from the Neurogenetics Unit in Hospital
Ramos Mejía, Buenos Aires. We reanalysed them with
GenIO, obtaining, in the final inherit model output lists,
all the known genes that were previously considered as
disease causing (Additional file 1: Table S1). In previously
undiagnosed cases, we had no additional yield. GenIO was
also successfully validated with different well known cases
such as Miller syndrome in Ng et al., 2010 [22], Nature
Genetics (causative gene: DHODH), and with Schinzel-
Table 1 Comparison with other web servers features
Feature \ Web servers PhenIX eXtasy OMIM Explorer Phen-Gen wAnnovar GenIO
Year of last update 2014 2013 2016 2013 2015 2017
Simple Input interface Yes Yes No Yes Yes Yes
Acceptance of VCF files Yes Yes Yes Yes Yes Yes
Phenotype (HPO terms) Yes Yes Yes IDs only Yes Yes
Phenotype (OMIM terms) No No Yes No Yes Yes
List of genes of interest to analyze No No Yes No No Yes
Customizable Rareness of the condition Yes No Yes Yes Yes Yes
Fast responsive interface Yes Yes No Yes Yes Yes
No need of extra files to run Yes Yes Yes No Yes Yes
Trio datasets No No No Yes No No
Freeform text input No No Yes No No No
Email notification No Yes No Yes Yes Yes
Dominant and Recessive in single run Yes No Yes No Yes Yes
Can be used by a medical practitioner Yes No Yes No Yes Yes
Output interface with results Yes No Yes No Yes Yes
Simple Output interface Yes – No – Yes Yes
ACMG-AMP Classification No No No No No Yes
M-CAP Classification No No No No No Yes
ClinVar Classification Top 20 only No No No Yes Yes
ACMG Secondary findings No No No No No Yes
Full VCF annotation No No No No Yes Yes
Handful set of candidate variants Yes No Yes Yes Yes Yes
Session saving No Yes Yes Yes Yes Yes
Phenotype suggestion No No Yes No No No
Secure server (https) No No No No No Yes
Multi-nucleotide variants Yes No Yes Yes Yes Yes
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Giedion syndrome in Hoischen et al., 2010 [23], Nature
Genetics (causative gene: SETBP1), both included as ex-
amples in the GenIO web server.
The benchmarking performed on GenIO with the sim-
ulated dataset identified the candidate pathogenic gene
variants in the recessive or dominant inheritance models
in 94 out of the 125 cases, obtaining a sensitivity of the
75.2%. It should be noted that the inheritance model fil-
ters applied in GenIO (see Implementation section) do
not rely on the ClinVar clinical significance annotations,
making this benchmark completely unbiased. All these
tests were run with GenIO default parameters.
We compared GenIO with other existing clinical gen-
omics webtools in terms of features and usability from a
clinician user perspective. The compared web servers
are wAnnovar, Omim Explorer, eXtasy, PhenIX and
Phen-Gen (Table 1).
Finally, to further evaluate the performance of GenIO,
we evaluated these same web servers on clinical results
comparing 10 of the former analysed cases with defini-
tive diagnosis to find the causative gene under the same
input parameters (Additional file 1: Table S2).
Discussion
GenIO results may enable diagnosis confirmation, and
the output information will eventually help to identify
the optimal treatment and clinical management for the
patient. If, after analysis, the patient still lacks a clear eti-
ology, the output information from GenIO can be used
to launch a query on Matchmaker Exchange [24] plat-
form to find additional cases with a deleterious variant
in the same listed genes or with overlapping phenotype,
which may provide sufficient evidence to identify the
causative gene.
The quality of the variants identified in the VCF file
uploaded by the user represents limitations to this clin-
ical genomics analysis system. Since the raw sequences
or genotype data is pre-processed and filtered before it
is saved in a VCF format file, we are not able to ensure
the quality of previous data processing, and have to as-
sume an acceptable variant quality, and therefore a trust-
worthy variant call. We do, nevertheless, validate the
format of the VCF file and filter out variants that did not
pass the quality thresholds.
Although trio analysis is necessary for the detection of
de novo mutations, GenIO does not support this ana-
lysis. As the list of de novo variants is usually small
enough to be manually interpretable, usually does not
require further interpretation.
The manual update of the GenIO’s annotation databases
represents another limitation to the predictive perform-
ance. While clinical research evidence is being generated
at ever faster rates, much of this evidence is not readily
available in databases. Quality of the databases is also a
possible limitation, as clinical databases may include
wrong annotations. GenIO works with trustable sources,
but nevertheless, they still could contain errors.
Conclusions
GenIO’s intuitive and user-friendly interface was de-
signed to be used not only by clinical genomics re-
searchers, but also by medical doctors. Its simple input
interface and the use of controlled vocabulary to enter
clinical information minimize spelling and writing errors
while entering the patient’s phenotypic information. Its
diagnosis-oriented output presents only a small manage-
able number of the most probable recessive and domin-
ant candidate gene variants associated with the rare
disease case. Most of the existing clinical genomics web
servers supporting diagnosis tasks are scientifically ori-
ented and not designed to be used by medical doctors,
on which we experienced some usability problems. In
this sense, GenIO is one of the first public web servers
developed with the aim of bringing new clinical genom-
ics tools to the medical and scientific community.
Future work will include the identification of pharma-
cogenomic variants, the development of integrative visu-
alizations for an improvement in the variant clinical
interpretation, migration to a cloud computing architec-
ture to handle bigger datasets, the development of a nat-
ural language processing of electronic medical records
for phenotype suggestions, and the implementation of





Operating system(s): Platform independent.
Programming language: Javascript, PHP, GNU-bash shell.
Other requirements: Phenolyzer (v.1.0.5), Annovar
(v.2017Jul17)(v.2015Dec14), Anntools (v.1.1), and SnpEff
(v.4.2).
License: GNU General Public License.
Any restrictions to use by non-academics: licence needed.
Additional file
Additional file 1: Table S1. Validated exomes with definitive diagnosis.
Table S2. GenIO performance comparison. (DOCX 77 kb)
Abbreviations
ACMG SF: ACMG Secondary Findings; ACMG-AMP: American College of
Medical Genetics and Genomics and the Association of Molecular Pathology;
gnomAD: The Genome Aggregation Database; HPO: Human Phenotype
Ontology; IBioBA: Instituto de Investigación en Biomedicina de Buenos Aires;
M-CAP: Mendelian Clinically Applicable Pathogenicity; OMIM: Online
Mendelian Inheritance in Man; VCF: Variant Call Format
Koile et al. BMC Bioinformatics  (2018) 19:25 Page 5 of 6
Acknowledgements
All the authors are members of the Argentine National Research Council
(CONICET). This work was funded by grants from CONICET, ANPCyT and
FOCEM-Mercosur.
Funding
All the authors are members of the Argentine National Research Council
(CONICET). This work was funded by grants from CONICET, ANPCyT and
FOCEM-Mercosur.
Availability of data and materials
Patients data are from the Cordoba M, Rodriguez-Quiroga S, Vega P, Amartino
H, Vazquez-Dusefante C, Medina N, et al. Whole Exome Sequencing in
Neurogenetic Diagnostic Odysseys: An Argentinian Experience. bioRxiv
060319 (2016) study whose authors may be contacted at the email of the article
corresponding author Dr. Marcelo Kauffman (marcelokauffman@gmail.com) to
access the anonymized data. The data cannot be publicly deposited due to
patient privacy. The benchmarking simulated dataset used and analysed during
the system validation are available from the corresponding author on request.
Authors’ contributions
PY MK MC conceived and designed the tool. DK PY MSS implemented the
tool. MC MK performed the experiments and comparisons. MC DK MSS MK
PY analysed the data. PY MK DK wrote the paper. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
The validation retrospective study was approved by the Ethics Committee
and Institutional Review Board of the Hospital JM Ramos Mejia, informed





The authors declare that they have no competing interests
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET
- Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
2Consultorio de Neurogenética, Centro Universitario de Neurología y División
Neurología, Hospital J.M. Ramos Mejia, Facultad de Medicina, UBA, Buenos
Aires, Argentina. 3Programa de Medicina de Precisión y Genómica, Instituto
de Investigaciones en Medicina Traslacional, Facultad de Ciencias
Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina.
Received: 9 October 2017 Accepted: 15 January 2018
References
1. Stavropoulos DJ, et al. Whole-genome sequencing expands diagnostic
utility and improves clinical management in paediatric medicine. Genomic
Medicine. 2016;1:15012.
2. Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating
genetic risk information for common disorders in the era of genomic
medicine. Annu Rev Genom Human Genetics. 2013;14:491–513.
3. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al.
ClinVar: public archive of interpretations of clinically relevant variants.
Nucleic Acids Res. 2016 Jan;44(D1):D862–8.
4. Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN,
et al. M-CAP eliminates a majority of variants of uncertain significance in
clinical exomes at high sensitivity. Nat Genet. 2016 Oct;48(12):1581–6.
5. Li Q, Wang K. Intervar: clinical interpretation of genetic variants by the 2015
ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–280.
6. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology. Genetics in Medicine. 2015 May;
17(5):405–24.
7. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations
for reporting of secondary findings in clinical exome and genome sequencing,
2016 update (ACMG SF v2.0): a policy statement of the American College of
Medical Genetics and Genomics. Genetics in Medicine. 2016 Nov;19(2):249–55.
8. Yang H, Wang K. Genomic variant annotation and prioritization with
ANNOVAR and wANNOVAR. Nat Protoc. 2015 Sep;10(10):1556–66.
9. James RA, Campbell IM, Chen ES, Boone PM, Rao MA, Bainbridge MN, et al.
A visual and curatorial approach to clinical variant prioritization and disease
gene discovery in genome-wide diagnostics. Genome Med. 2016;8(1):13.
10. Sifrim A, Popovic D, Tranchevent LC, Ardeshirdavani A, Sakai R, Konings P, et
al. eXtasy: variant prioritization by genomic data fusion. Nat Methods. 2013
Nov;10(11):1083–4.
11. Zemojtel T, Köhler S, Mackenroth L, Jäger M, Hecht J, Krawitz P, et al.
Effective diagnosis of genetic disease by computational phenotype analysis
of the disease-associated genome. Sci Transl Med. 2014;6(252):252ra123.
12. Javed A, Agrawal S, Ng PC. Phen-gen: combining phenotype and genotype
to analyze rare disorders. Nat Methods. 2014 Sep;11(9):935–7.
13. Köhler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Aymé S, et al. The
human phenotype ontology in 2017. Nucleic Acids Res. 2017 Jan;45(D1):D865–76.
14. Glusman G, Cariaso M, Jimenez R, Swan D, Greshake B, Bhak J, et al. Low
budget analysis of direct-to-consumer genomic testing familial data.
F1000Research. 2012;1:3.
15. Cordoba M, Rodriguez-Quiroga S, Vega P, Amartino H, Vazquez-Dusefante C,
Medina N, et al. Whole Exome Sequencing in Neurogenetic Diagnostic
Odysseys: An Argentinian Experience. bioRxiv 060319. 2016. https://doi.org/
10.1101/060319
16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res. 2010
Sep;38(16):e164.
17. Makarov V, O’Grady T, Cai G, Lihm J, Buxbaum JD, Yoon S. AnnTools: A
comprehensive and versatile annotation toolkit for genomic variants.
Bioinformatics (Oxford, England). 2012 Mar;28(5):724–5.
18. Cingolani P, Platts A, Wang Ie L, Coon M, Nguyen T, Wang L, et al. A
program for annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila Melanogaster
strain w1118; iso-2; iso-3. Fly. 2012 Apr;6(2):80–92.
19. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al.
Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016
Aug;536(7616):285–91.
20. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:
the NCBI database of genetic variation. Nucleic Acids Res. 2001 Jan;29(1):308–11.
21. Yang H, Robinson PN, Wang K. Phenolyzer: phenotype-based prioritization
of candidate genes for human diseases. Nat Methods. 2015 Sep;12(9):841–3.
22. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, et al. Exome
sequencing identifies the cause of a mendelian disorder. Nat Genet. 2009
Nov;42(1):30–5.
23. Hoischen A, van Bon BWM, Gilissen C, Arts P, van Lier B, Steehouwer M, et
al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat
Genet. 2010 Jun;42(6):483–5.
24. Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M,
et al. The matchmaker exchange: a platform for rare disease gene discovery.
Hum Mutat. 2015 Oct;36(10):915–21.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Koile et al. BMC Bioinformatics  (2018) 19:25 Page 6 of 6
